Cytomegalovirus (CMV) disease is a common complication of advanced human immunodeficiency virus (HIV) infection. Administration of oral valaciclovir, a valine ester of acyclovir, achieves sufficient plasma acyclovir levels to inhibit many clinical isolates. Acyclovir has been associated with enhanced survival in AIDS but not with CMV disease prevention. CMV-seropositive patients (1227) with CD4 cell counts õ100/mm 3 were enrolled in a randomized, double-blind trial. Valaciclovir, 8 g/day, was compared with acyclovir, 3.2 or 0.8 g/day, for CMV prevention; all three arms were compared for survival. The confirmed CMV disease rate was 11.7% among valaciclovir recipients and 17.5% in the pooled acyclovir arms, a 33% reduction in risk. Time to confirmed CMV disease was significantly longer for the valaciclovir group (P Å .03). A trend toward earlier mortality for valaciclovir recipients was seen (P Å .06). Toxicity and earlier medication discontinuation were more common in this group. Valaciclovir significantly reduces the risk of CMV disease. Further exploration of a better-tolerated dose is warranted.
Valaciclovir for CMV Prophylaxis in AIDS of 18 pills per day. All medications considered essential for optimal daily, which is sufficient to inhibit many clinical strains of care were permitted, except anti-CMV agents and immunomodula-CMV [9] .
tors. Simultaneous enrollment in other studies of HIV disease manOral acyclovir prophylaxis for recurrent herpes simplex virus agement was encouraged.
(HSV) infections is commonly used in patients with advanced
Design and study conduct. Comparison of the valaciclovir arm HIV disease. Two prospective randomized studies of such pawith the pooled acyclovir arms for the prevention of CMV endtient populations have shown a survival advantage associated organ disease, provided the acyclovir arms were not different, was with high-dose acyclovir compared with placebo [10, 11] but specified in the protocol. The higher acyclovir dose (3.2 g/day) no significant effect on the development of CMV disease, and had been shown in two previous placebo-controlled trials to be a third study failed to demonstrate an effect on CMV cultures ineffective for preventing CMV disease in patients with advanced [12] . Retrospective studies have demonstrated discordant re-HIV infection [10, 11] , and it was anticipated that the lower dose of acyclovir would also be ineffective. The 3.2 g/day dose was sults on mortality with acyclovir use [13, 14] . It is possible associated with a survival advantage in these studies, so investigathat clinically silent herpesvirus replication may up-regulate tion of the effect of both lower and higher delivered doses of HIV replication [15, 16] , an effect that could be mitigated by acyclovir was planned to explore a possible dose-effect relationacyclovir.
ship. This analysis would compare the survival experience of the We conducted a randomized, double-blind, comparative three arms in pairwise fashion. A target sample size of 1200 pastudy of valaciclovir, 2 g four times daily, and two doses of tients, with 12 months of planned follow-up after entry of the last oral acyclovir for the prevention of CMV end-organ disease subject, was selected to provide at least 82% power to detect an and mortality in persons with advanced HIV disease. A pharapproximate doubling of the median CMV-free time for valacimacokinetic study defined this valaciclovir dose as the maxiclovir relative to the pooled acyclovir arms and to detect a 55% mum tolerated dose in AIDS patients [8] . A high dose of increase in median survival for pairwise comparison among the acyclovir, 800 mg four times daily, was the dose used in the three arms.
Participants were evaluated at baseline, week 4, and week 8 and placebo-controlled trials that reported a survival benefit without every 8 weeks thereafter. At each visit, blood was obtained for affecting CMV disease incidence [10, 11] . A lower dose, 400 routine laboratory tests, serum and plasma specimens were banked, mg twice daily, was chosen to suppress HSV recurrences and urine was cultured for CMV according to local methods, and qualto prevent possible unblinding that might occur with a placebo.
ity-of-life measures were assessed. CD4 cell counts and HIV p24
Use of three different delivered doses of acyclovir permitted antigen determinations were obtained every 24 weeks.
exploration of a possible dose-effect relationship on survival.
As this was a collaborative effort of the AIDS Clinical Trials Group (ACTG) and investigators in Europe, Canada, and Australia, an International Steering Committee was formed with appropriate
Methods
representation. The committee met semiannually and provided overall governance to the diverse study sites. Subjects. Eligible subjects were §13 years old, with laboratory evidence of HIV infection or a clinical diagnosis of AIDS, Dose modification and toxicity management. Since acyclovir is generally well-tolerated, even by patients with advanced HIV an absolute CD4 lymphocyte count õ100/mm 3 , serologic evidence of prior CMV infection, a Karnofsky performance score §60, and disease, study drug dosing was modified only for diminished renal function (estimated creatinine clearance, õ50 mL/min) that would no evidence of CMV end-organ disease. All participants were evaluated for possible retinitis within 21 days before entry by an impair acyclovir elimination. When significant toxicity (grade 3 or higher according to the standard ACTG toxicity grading scheme) experienced ophthalmologist who used dilated indirect fundoscopy. Patients with symptoms associated with extraocular CMV occurred, a trial of interruption, dose reduction, or discontinuation was advised for potentially toxic nonstudy medications. If the syndromes were required to undergo additional medical evaluation as indicated to rule out preexisting CMV disease. Participants had toxicity did not resolve, study drug was then interrupted. If toxicity attributed to study drug did not resolve within 30 days, study to be receiving all medications for HIV and opportunistic infections for at least 30 days before entry; there were no restrictions medication was permanently discontinued until a protocol amendment (July 1994) allowed patients to restart study drug after an on these therapies.
Patients were ineligible if they had chronic nausea or vomiting, interruption of up to 6 months for any reason. Study drug formulation included 3.6, 10.9, and 13.4 g of lactose/day for valaciclovir, ocular media opacities, or necrotizing retinopathy, were pregnant or breast-feeding, had a history of hypersensitivity to acyclovir or high-dose acyclovir, and low-dose acyclovir, respectively. Symptoms suggestive of lactose intolerance were managed with dietary known lactose intolerance, had received immunomodulators within 30 days before entry, had previously received anti-CMV agents, modification or a trial of lactase (or both). CMV disease end-point evaluations. Study ophthalmologists or had any of the following laboratory values: absolute neutrophil count õ500/mm 3 , estimated creatinine clearance õ50 mL/min, performed dilated indirect funduscopy in all subjects every 24 weeks and whenever new visual complaints arose. Retinal photototal bilirubin ú5 mg/dL, or serum aminotransferase ú5 times the upper limit of normal.
graphs were taken to document CMV retinitis and were verified by an independent fundus photograph reading center that was Randomization and treatment. Participants were randomized in a 3:2:2 ratio to valaciclovir, 2 g four times daily, high-dose masked to study drug assignment. Participants were evaluated at both scheduled and symptom-driven visits for signs and symptoms acyclovir, 800 mg four times daily, or low-dose acyclovir, 400 mg twice daily. Patients were stratified by baseline CD4 cell count:
of possible extraocular CMV disease by use of a standardized questionnaire. Additional medical assessment was directed by the õ50 and 50-100/mm 3 . Double-blinding required administration JID 1998; 177 (January) site investigator. The valaciclovir arm was compared with the two pooled nominal data. Product-limit estimates were used to summarize acyclovir arms for prevention of CMV disease, according to time-to-event data [17] . The log rank test was used for comparing the protocol, because the two acyclovir arms were similar time-to-event distributions [18, 19] . Cumulative incidence analysis (P Å .67). The confirmed end-point rates were 11.7% and was done to assess the risk of developing CMV disease in the face 17.5% for valaciclovir and acyclovir, respectively, representing of competing mortality [20] . All tests of significance were twoa 33% reduction for those randomized to valaciclovir. Time sided. All P values reported are nominal P values, unadjusted for to confirmed CMV disease was significantly longer for the interim analyses or for multiple comparisons.
valaciclovir group than for those assigned to acyclovir (P The study was monitored by an independent data and safety Å .03; figure 1). ported (confirmed plus presumptive) end points were considered, the protective effect of valaciclovir in delaying time to first CMV disease persisted (P Å .009; table 2). Considering Results only the 122 end points (66%) that occurred while participants were receiving assigned study medication or within 14 days Study population. Enrollment of 1227 subjects at 72 sites began in December 1992 and ended in October 1994. Sixtyof its discontinuation (as-treated analysis), valaciclovir was significantly more effective than acyclovir (P Å .006). In a six percent were enrolled at ACTG sites in the United States and 34% at sites in Canada, Australia, and Europe. Seventy cumulative incidence analysis of CMV end points that accounted for the competing risk of death, valaciclovir signifiparticipants (5.7%) had 73 eligibility exemptions, primarily for laboratory values out of range or out of date. Participants were cantly reduced the risk of CMV disease relative to acyclovir (P Å .006). primarily white, non-Hispanic (79.8%) men (93.9%) who had never injected drugs (92.3%). The treatment arms were compaBaseline positive urine cultures were predictive of future CMV disease. Seventy-nine CMV end points (23.9%) occurred rable with respect to selected baseline characteristics (table 1) . Fewer than half (44.6%) had urine cultures positive for CMV among those with positive cultures at entry, whereas only 46 (11.2%) occurred among those with negative cultures (P at entry. The median CD4 cell count was 32/mm 3 , and 67.9% had õ50 cells/mm 3 . Prophylaxis for Pneumocystis carinii õ .001). In multivariate analyses that included baseline demographics, laboratory values, urine culture results, time of urine pneumonia, Mycobacterium avium complex (MAC) infection, and fungal infections were used by 96.5%, 26.2%, and 53.3%, culture conversion, other diagnoses, and antiretroviral use, valaciclovir was significantly protective (P õ .05). A greater respectively, and was balanced among the arms. There were no significant differences in the use of one or more antiretroviprotective effect was seen in the higher CD4 cell count stratum ( §50) at entry, with rates of 4% and 16%, respectively, for ral agents (zidovudine, didanosine, zalcitabine, stavudine, or nevirapine), taken by 79.2% overall, or for prior diagnoses of valaciclovir and the pooled acyclovir arms (P Å .001) compared with 15% and 18%, respectively, for those with entry HSV or varicella-zoster virus infection, Kaposi's sarcoma, P. carinii pneumonia, or disseminated MAC infection. The CD4 cell count õ50 (P Å .57). CMV retinitis accounted for 79.3% of end points and gastromedian duration of study treatment was 29, 36, and 40 weeks for valaciclovir, high-dose acyclovir, and low-dose acyclovir, intestinal disease for 15.2%; other diagnoses were relatively infrequent (table 3) . Despite small numbers, a proportional respectively; however, the median duration of follow-up was comparable at 57, 56, and 60 weeks. Loss to follow-up rates reduction in all CMV diagnoses was seen for valaciclovir. There were no significant differences among the arms with by study arm (7.1%, 7.9%, and 4.3% for valaciclovir, high- regard to the development of varicella-zoster virus or HSV among the 411 patients who were culture-negative at entry (P õ .001) and decreased the duration of viral shedding among infections or for new diagnoses of Kaposi's sarcoma.
Antiviral activity. The effect of valaciclovir on recovery of the 331 who were culture-positive at entry (P Å .003; figure  2 ). Although viral shedding may be intermittent in the absence CMV from urine cultures was analyzed according to whether the baseline culture result was negative or positive. Valaciclovir of specific anti-CMV therapy, these results suggest that valaciclovir had a greater antiviral effect than acyclovir. Antiviral both significantly delayed the time to first positive culture (VACV) significantly delayed time to first confirmed CMV disease ‡ Only patients' first confirmed end point was considered for primary analysis. compared with pooled acyclovir (ACV) arms (P Å .03, log rank test).
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10-31-97 15:31:45 jinfal UC: J Infect treatment arm was compared with other 2 arms. There was trend to ‡ Encephalitis, radiculomyopathy.
earlier mortality in valaciclovir (VACV) group (P Å .06, log rank test) compared with high-and low-dose acyclovir (HACV, LACV).
activity as assessed by polymerase chain reaction is described in the companion paper by Griffiths et al. [22] . rates of 24.1%, 19.5%, and 18.8%. Pairwise comparisons sugSurvival. There were 488 deaths overall (39.8%). A trend gested that the risk of death was greater for valaciclovir than toward earlier mortality was seen for patients randomized to for low-dose acyclovir (HR, 1.28; 95% CI, 1.03 -1.59), with valaciclovir (P Å .06; figure 3). Mortality rates were 42.6%, no significant difference between valaciclovir and high-dose 38.2%, and 37.0% for valaciclovir, high-dose acyclovir, and acyclovir (HR, 1.17; 95% CI, 0.94 -1.45) or between the two low-dose acyclovir, respectively, with estimated 12-month acyclovir arms (HR, 1.10; 95% CI, 0.87 -1.40). Only 57 deaths (11.7%) occurred in patients who were still receiving assigned study medication or within 14 days of its discontinuation. In an as-treated analysis, survival was significantly shorter in the valaciclovir arm (P Å .002). Mortality was similar among those who had positive or negative urine CMV cultures at entry, with 137 (41.4%) and 148 (36.0%) deaths, respectively (P Å .13). Multivariate analyses revealed an increased risk of death in patients receiving valaciclovir when baseline demographics, laboratory values, diagnoses, antiretroviral use, and time of elevated serum creatinine were considered (P õ .05).
The most common principal cause of death, in 44 patients (9.0% of all deaths), was non-Hodgkin's lymphoma, evenly divided between systemic and primary central nervous system disease. Other common causes of death were non -P. carinii pneumonia (8.8%), disseminated MAC infection (8.6%), wasting (7.8%), P. carinii pneumonia (7.4%), sepsis (6.8%), and Kaposi's sarcoma (6.6%). CMV disease was listed as the principal cause of death for 16 patients (3.3%). There were no significant differences in the primary causes of death among the three arms.
Tolerance. Of all adverse events grade 3 or higher, only gastrointestinal complaints occurred significantly more often and earlier in the valaciclovir arm (P Å .03). Grade 2 or greater increases in serum creatinine (ú1.5 times the upper limit of normal) occurred earliest in the valaciclovir group (P Å .03), although there were no differences among the arms for grade 1 or higher increases (P Å .11). Sixty-five patients had an Eighteen patients developed an illness with features suggescontrolled trial using the same dose of ganciclovir failed to confirm this result [25] . Secondary analyses that included pretive of thrombotic microangiopathy (TMA), reported as thrombocytopenic purpura or hemolytic-uremic syndrome, 8 of sumptive diagnoses and end points that occurred while patients were receiving treatment or within 14 days of its discontinuawhom were still receiving assigned study medication. Most cases failed to meet established criteria for classical thrombocytion, as well as evidence of an antiviral effect on recovery of virus from urine, support the superiority of valaciclovir in topenic purpura or hemolytic-uremic syndrome, with milder thrombocytopenia and anemia, rare neurologic abnormalities, delaying CMV disease compared with acyclovir. This is the first randomized trial of CMV prophylaxis in poor response to plasma therapy when administered, and prolonged survival without plasma therapy. The reported events which all end points were independently confirmed. Cases of retinitis were evaluated by an independent retinal photograph occurred a median of 54 weeks after enrollment (range, 8 -84) . TMA-like syndromes were reported more frequently in the reading center, and extraocular disease was assessed by a panel of blinded investigators. Protocol criteria for confirmed extravalaciclovir arm (14) than in either of the acyclovir arms (highdose acyclovir, 1; low-dose acyclovir, 3; P Å .008). Those ocular disease were stringent, requiring a compatible clinical syndrome and evidence of CMV-related tissue invasion. Fortyrandomized to valaciclovir had received doses of 8 g/day for a median of 54 weeks (range, 8 -77) , and 12 had been treated eight patients who received a clinical diagnosis of CMV endorgan disease lacked key data for independent confirmation, for ú35 weeks. Patients with TMA-like syndromes received multiple medications, and most had intercurrent illnesses that and 18 cases that were fully evaluated failed to meet predetermined criteria. Sixteen of these were presumptive diagnoses of could explain the hematologic and renal abnormalities. The relative risk of a TMA-like event was increased among recipiextraocular disease, which may reflect the difficulty in establishing an unequivocal diagnosis in clinical practice or the strict ents of a number of concomitant medications, including clofazimine, fluconazole, ciprofloxacin, ethambutol, and trimethocase definitions used. In contrast, clinical diagnosis of CMV retinitis by experienced ophthalmologists appears sufficient for prim-sulfamethoxazole, as well as valaciclovir. These cases and associated risk factors are more fully described elsefuture trials. A trend to earlier mortality was seen in the valaciclovir where [23] .
Treatment discontinuation. The treatment arms differed in group compared with the acyclovir arms. Two randomized double-blind trials that compared high-dose acyclovir with platime to permanent discontinuation of study medication for reasons other than death or the development of CMV disease, cebo in patients with advanced HIV disease (median CD4 cell count, 39 and 32/mm 3 ) reported annual mortality estimates of with those assigned to valaciclovir discontinuing earlier (P Å .01). The overall estimated 12-month discontinuation rate 23% and 27% for the high-dose acyclovir recipients compared with 39% and 46%, respectively, for the placebo groups was 46.6%. The respective rates for valaciclovir, high-dose acyclovir, and low-dose acyclovir were 50. 5%, 46.2%, and [10, 11] . The current study, which lacked a placebo arm, had similar annual mortality rates, with 18.8%, 19.5%, and 24.1% 41.0%. Patients randomized to valaciclovir discontinued dosing significantly more often for protocol-defined toxicity (P for low-dose acyclovir, high-dose acyclovir, and valaciclovir, respectively. Differences that may have an impact on mortality, Å .001), with a trend toward earlier discontinuation for subjective complaints (P Å .07), while those assigned to acyclovir such as baseline HIV load, are not available. Patients with less advanced HIV disease (CD4 cell count, 100 -300/mm 3 ) treated discontinued treatment significantly more often for the development of CMV disease (P Å .001). Participants cited pill burden with high-dose acyclovir or placebo for a median of 365 days had no difference in survival, although median time to death (8.4%) and gastrointestinal complaints (7.1%) as their most common reasons for self-initiated discontinuation, with no sigwas long (945 days) [26] . Additional support for the concept that inhibition of herpesvirus replication may improve survival nificant differences among the arms.
in AIDS has come from a recent well-designed observational study [14] , although a second observational study did not find Discussion a survival advantage [13] ; this discordance may result from methodologic concerns [27] . Two placebo-controlled studies This study was designed to compare valaciclovir, 2 g four times daily, with high-and low-dose acyclovir (arms comof oral ganciclovir prophylaxis for CMV disease demonstrated a trend to enhanced survival for ganciclovir recipients [24, 25] . bined) for the prevention of CMV disease in patients with advanced HIV infection and for pairwise comparison of the The results of the study reported here may provide some insight into which herpesviruses are responsible for this effect. three different delivered acyclovir doses for survival. A significant protective effect for valaciclovir against CMV disease
As there was no significant difference between high-and lowdose acyclovir, improved survival may be due to suppression of was demonstrated, with a 33% reduction in the rate of confirmed CMV end-organ disease and significant prolongation of the most sensitive herpesviruses, such as HSV-1 or -2. Further support for this possibility comes from evidence that HSV the time to development of CMV disease (P Å .03). A 49% reduction in the rate of confirmed CMV end-organ disease has infection in human skin is associated with increased numbers of HIV virions, possibly HIV/HSV pseudotypes, and that reacpreviously been demonstrated in a placebo-controlled study of oral ganciclovir, 1 g three times daily [24] . A second placebotivation of HSV-2 can increase HIV plasma RNA levels [28, JID 1998; 177 (January) Andersen ( 
